Scarica l'app Stockscreener
9.14
1.33%
0.12
Pre-mercato:
9.10
-0.04
-0.44%
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
623,600 Shares in Intellia Therapeutics, Inc. $NTLA Acquired by Marex Group plc - MarketBeat
Intellia Therapeutics, Inc. $NTLA Shares Sold by Nikko Asset Management Americas Inc. - MarketBeat
Is Intellia Therapeutics Inc 38I a good long term investment - earlytimes.in
Intellia Therapeutics, Inc. $NTLA Shares Purchased by Armistice Capital LLC - MarketBeat
(NTLA) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
JPMorgan Chase & Co. Purchases 396,858 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Volume Recap: Will Intellia Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Action & Free Weekly Watchlist of Top Performers - moha.gov.vn
Intellia Therapeutics (NASDAQ:NTLA) Nasdaq Index Expands Genetic Research - Kalkine Media
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Why Intellia Therapeutics (NTLA) Is Up 6.9% After Disclosing Serious Liver Safety Events In Lead CRISPR Trials - Sahm
Would You Still Hold Intellia Therapeutics Stock If It Fell Another 30%? - Trefis
Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Should Contact Levi & Korsinsky About Pending Class ActionNTLA - 28/22 News
Schroder Investment Management Group Increases Stock Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Focuses on Pipeline Development Amid Stiff Competition - MSN
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Will Intellia Therapeutics Inc. (38I) stock benefit from mergersJuly 2025 Momentum & Weekly Stock Performance Updates - Newser
How analysts revise price targets for Intellia Therapeutics Inc. (38I) stockWeekly Risk Report & Accurate Technical Buy Alerts - Newser
Intellia Therapeutics (NASDAQ: NTLA) issues 12,600 inducement RSUs to three new employees - Stock Titan
Will Intellia Therapeutics Inc. (38I) stock recover faster than industryMarket Volume Summary & Technical Pattern Alert System - Newser
What dividend safety rating applies to Intellia Therapeutics Inc. (38I) stockMarket Sentiment Report & AI Based Trade Execution Alerts - Newser
Why analysts maintain buy rating on Intellia Therapeutics Inc. (38I) stockJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - Newser
Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory - Finviz
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.1%Should You Buy? - MarketBeat
Does Intellia Therapeutics Inc. (38I) stock trade below intrinsic valueQuarterly Portfolio Review & Fast Exit and Entry Trade Guides - Newser
Is Intellia Therapeutics Inc. stock attractive for growth ETFs2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - Newser
Why Intellia Therapeutics Inc. (38I) stock remains top ratedWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
What is the fair value estimate for Intellia Therapeutics Inc. (38I) stock in 2025Trend Reversal & Accurate Entry/Exit Alerts - Newser
Will Intellia Therapeutics Inc. (38I) stock outperform value peersJuly 2025 Summary & Technical Pattern Based Buy Signals - Newser
Will Intellia Therapeutics Inc. (38I) stock profit from AI boomMarket Activity Summary & Capital Protection Trade Alerts - Newser
Intellia Therapeutics: Critical Safety Updates Are ImminentExpect Volatility (NTLA) - Seeking Alpha
Is Intellia Therapeutics Inc. (38I) stock nearing a technical breakout2025 Price Targets & Weekly High Momentum Picks - Newser
Can Intellia Therapeutics Inc. (38I) stock survive global slowdown - Newser
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble - MSN
Intellia Therapeutics (NASDAQ:NTLA) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Geode Capital Management LLC Boosts Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Can Intellia Therapeutics (NTLA) Rebuild Trust Amid Safety Setbacks and Regulatory Challenges? - Sahm
How (NTLA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade - Yahoo Finance
Intellia Therapeutics, Inc. $NTLA Shares Sold by Orchard Capital Management LLC - MarketBeat
Pullback Watch: Will Intellia Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Weekly Recap & Intraday High Probability Alerts - moha.gov.vn
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? - Nasdaq
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? - sharewise.com
Will Intellia Therapeutics Inc. stock remain a Wall Street favorite2025 Geopolitical Influence & Accurate Intraday Trading Signals - BỘ NỘI VỤ
Operating cash flow per share of Intellia Therapeutics, Inc. – LSX:A2AG6H - TradingView
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of "Hold" from Analysts - MarketBeat
5 Stocks with the Largest Fair Value Estimate Cuts After Q3 Earnings - Morningstar
Intellia Therapeutics Shares: A Crisis Crossroads - Ad-hoc-news.de
Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress - MSN
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):